London
· Delayed Price · Currency is GBP · Price in EUR ABIONYX Pharma Company Description
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases.
It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis.
The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019.
ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
| Country | France |
| Founded | 2005 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 61 |
| CEO | Cyrille Tupin |
Contact Details
Address: 33 43 av. Georges Pompidou Bât. D2 Balma, 31130 France | |
| Phone | 33 5 62 24 97 06 |
| Website | abionyx.com |
Stock Details
| Ticker Symbol | 0RAG |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sir Cyrille Tupin CPA | Chief Executive Officer, GM and Director |
| Prof. Christian Chavy | Independent Director |
| Emmanuel De Fougeroux | Chief Accounting Officer and Chief Financial Officer |
| Renee Benghozi | Chief Medical Officer |
| Gavin Sy | Chief Production Officer |
| Constance Keyserling | Senior Vice President of Clinical Development |